Minakem Header W48

Minakem Header W48

X

[{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$30.0 million","newsHeadline":"Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE\u00ae Technology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Halozyme Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of Xeljanz\u00ae in Rheumatoid Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada has Initiated a Safety Review On Xeljanz and Xeljanz XR (Tofacitinib), Used to Treat Arthritis and Ulcerative Colitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pfizer Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OLUMIANT\u00ae Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Janssen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New TREMFYA\u00ae (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful LongTerm Improvement in Health-Related Quality of Life","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Janssen Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Janssen Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful LongTerm Improvement in Health-Related Quality o...

Details:

TREMFYA (guselkumab) is a fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is an important driver of the pathogenesis of inflammatory diseases.

Lead Product(s): Guselkumab

Therapeutic Area: Immunology Product Name: Tremfya

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 10, 2022

ASK
US

Upload
your Pipeline Activity

Eli Lilly

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis

Details:

Among those treated with OLUMIANT, the overall incidence rate of adverse events per 100 patient years of exposure was 22.6, and the incidence rate of serious adverse events was 7.4. Incidence rates remained stable over time across the 14,744 patient years of exposure.

Lead Product(s): Baricitinib

Therapeutic Area: Immunology Product Name: Olumiant

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Incyte Corporation

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 09, 2021

ASK
US

Upload
your Pipeline Activity

Pfizer Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Health Canada has Initiated a Safety Review On Xeljanz and Xeljanz XR (Tofacitinib), Used to Treat Arthritis and Ulcerative Colitis

Details:

Health Canada is informing Canadians and health care professionals that it is conducting a safety review of Xeljanz and Xeljanz XR (tofacitinib) after a clinical trial identified an increased risk of serious heart-related issues and cancer in trial participants.

Lead Product(s): Tofacitinib Citrate

Therapeutic Area: Immunology Product Name: Xeljanz

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2021

ASK
US

Upload
your Pipeline Activity

Pfizer Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of Xeljanz® in Rheumatoid Arthritis Patients

Details:

The co-primary endpoints of this study were non-inferiority of tofacitinib compared to TNFi in regard to major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer (NMSC)).

Lead Product(s): Tofacitinib Citrate

Therapeutic Area: Immunology Product Name: Xeljanz

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2021

ASK
US

Upload
your Pipeline Activity

Halozyme Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology

Details:

Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease.

Lead Product(s): Teprotumumab,rHuPH20

Therapeutic Area: Immunology Product Name: Tepezza

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Horizon Therapeutics

Deal Size: $190.0 million Upfront Cash: $30.0 million

Deal Type: Collaboration November 23, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY